

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

VERY SUBSTANTIAL DISPOSAL AND CONNECTED TRANSACTION: DISPOSAL OF THE TARGET SHARES IN THE TARGET COMPANIES

References are made to the announcement and the supplemental announcement of Yestar Healthcare Holdings Company Limited (the “**Company**”) dated 30 December 2022 and 23 March 2023 and the circular of the Company dated 13 December 2023 (the “**Circular**”) in relation to the Equity Transfer Agreement, pursuant to which the Vendor conditionally agreed to sell, and the Purchaser conditionally agreed to acquire the Target Shares at a Consideration of RMB574,750,000. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the conditions precedent under the Equity Transfer Agreement have been fulfilled and the Completion took place on 12 January 2024 in accordance with the terms of the Equity Transfer Agreement. Following the Completion, the Company has ceased to hold any equity interests in the Target Companies. Accordingly, the Target Companies have ceased to be the subsidiaries of the Company and will no longer be consolidated into the financial statements of the Group.

By order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
CEO and executive Director

Hong Kong, 12 January 2024

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.